Mariner
BOLT icon

Mariner’s Bolt Biotherapeutics BOLT Stock Holding History

Mariner’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,000
Closed -$16K – 3499
2025
Q1 		$16K Buy
2,000
+250
+14% +$2.4K ﹤0.01% 3391
2024
Q4 		$18.7K Sell
1,750
-277
-14% -$3.35K ﹤0.01% 3350
2024
Q3 		$26.3K Buy
+2,027
New +$27.9K ﹤0.01% 3232

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mariner's BOLT Position: Q2 2025 in Review

Mariner sold out of Bolt Biotherapeutics (BOLT) in Q2 2025, closing a stake of 2,000 shares — an estimated $16K sold.

Mariner first reported a position in BOLT in Q3 2024 and held it in 3 quarters. The position peaked at $26.3K in Q3 2024. 25 funds tracked by Wall St. Rank hold BOLT as of Q2 2025.

  • Mariner reported no remaining Bolt Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Mariner sold 2,000 Bolt Biotherapeutics shares in Q2 2025, an estimated $16K.
  • Mariner first reported a position in Bolt Biotherapeutics in Q3 2024 and held it in 3 quarters.
  • Mariner's Bolt Biotherapeutics position peaked at $26.3K in Q3 2024.
  • 25 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2025.

Based on Mariner's 13F filing for Q2 2025, filed 14 Aug 2025.